Abivax Q3 2024 update
Abivax has reported uneventful Q3 results, very much focused on balance sheet items and a recap of corporate achievements this year. On financials, Abivax reiterated its cash reach to Q4 2025 (unchanged) on a cash position exiting Q3 at EUR180.5m, pointing to estimated operating expenses of EUR41.8
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.